Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 29;24(7):6454.
doi: 10.3390/ijms24076454.

Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting

Pauline Henrot  1   2   3 , Isabelle Dupin  1   2 , Pierre Schilfarth  1   2   3 , Pauline Esteves  1   2 , Léo Blervaque  4 , Maéva Zysman  1   2   3 , Fares Gouzi  5 , Maurice Hayot  5 , Pascal Pomiès  4 , Patrick Berger  1   2   3
Affiliations
Review

Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting

Pauline Henrot et al. Int J Mol Sci. .

Abstract

Chronic obstructive pulmonary disease (COPD) is a worldwide prevalent respiratory disease mainly caused by tobacco smoke exposure. COPD is now considered as a systemic disease with several comorbidities. Among them, skeletal muscle dysfunction affects around 20% of COPD patients and is associated with higher morbidity and mortality. Although the histological alterations are well characterized, including myofiber atrophy, a decreased proportion of slow-twitch myofibers, and a decreased capillarization and oxidative phosphorylation capacity, the molecular basis for muscle atrophy is complex and remains partly unknown. Major difficulties lie in patient heterogeneity, accessing patients' samples, and complex multifactorial process including extrinsic mechanisms, such as tobacco smoke or disuse, and intrinsic mechanisms, such as oxidative stress, hypoxia, or systemic inflammation. Muscle wasting is also a highly dynamic process whose investigation is hampered by the differential protein regulation according to the stage of atrophy. In this review, we report and discuss recent data regarding the molecular alterations in COPD leading to impaired muscle mass, including inflammation, hypoxia and hypercapnia, mitochondrial dysfunction, diverse metabolic changes such as oxidative and nitrosative stress and genetic and epigenetic modifications, all leading to an impaired anabolic/catabolic balance in the myocyte. We recapitulate data concerning skeletal muscle dysfunction obtained in the different rodent models of COPD. Finally, we propose several pathways that should be investigated in COPD skeletal muscle dysfunction in the future.

Keywords: cachexia; interleukin; metabolism; myocyte.

PubMed Disclaimer

Conflict of interest statement

I.D. and P.B. have two patents delivered (EP no. 3050574, i.e., “Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease”, EP no. 20173595.8, i.e., “New compositions and methods of treating COVID-19 disease”). PB is the medical coordinator of the French national cohort (i.e., COBRA), which received grants from AstraZeneca, GlaxoSmithKine, Roche, Chiesi, Novartis and Legs Poix foundation. Moreover, PB reports grants and personal fees from Novartis, personal fees and nonfinancial support from Chiesi, grants, personal fees and nonfinancial support from Boehringer Ingelheim, personal fees and nonfinancial support from AstraZeneca, personal fees and nonfinancial support from Sanofi, personal fees from Menarini, personal fees from TEVA, outside the submitted work. All the other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the main histopathological alterations in COPD skeletal muscle. Alterations of skeletal muscle tissue in COPD result from both extrinsic factors (malnutrition, tobacco exposure, deconditioning) and intrinsic factors (hormonal imbalance, oxidative stress, inflammation, hypoxia and hypercapnia, and genetic and epigenetic modifications). Created with BioRender.com (accessed on 1 February 2023).
Figure 2
Figure 2
Alteration of the hypertrophy/atrophy balance leading to impaired protein turnover in COPD myocytes. Anabolic (hypertrophic) processes are represented in blue and catabolic (atrophic) in red. The chosen pathways have been identified as dysregulated in COPD patients or experimental models of COPD. IFN, interferon. IGF, insulin growth factor. IL, interleukin. MAPK, mitogen-activated protein kinase. Created with BioRender.com (accessed on 1 February 2023).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 310 Diseases and Injuries, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. - DOI - PMC - PubMed
    1. Rabe K.F., Watz H. Chronic Obstructive Pulmonary Disease. Lancet. 2017;389:1931–1940. doi: 10.1016/S0140-6736(17)31222-9. - DOI - PubMed
    1. Postma D.S., Bush A., van den Berge M. Risk Factors and Early Origins of Chronic Obstructive Pulmonary Disease. Lancet. 2015;385:899–909. doi: 10.1016/S0140-6736(14)60446-3. - DOI - PubMed
    1. Barnes P.J. Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 2000;343:269–280. doi: 10.1056/NEJM200007273430407. - DOI - PubMed
    1. Henrot P., Prevel R., Berger P., Dupin I. Chemokines in COPD: From Implication to Therapeutic Use. Int. J. Mol. Sci. 2019;20:2785. doi: 10.3390/ijms20112785. - DOI - PMC - PubMed

MeSH terms

Substances

Grants and funding

This research received funding by a grant from Fondation Bordeaux Université, with funding from AVAD and FGLMR.
-